

Exhibit 11

CVS Health Investor Fact Sheet and Investor Presentation December 4, 2017

CVS HEALTH ACQUISITION OF AETNA CREATES LEADING INTEGRATED HEALTH CARE PLATFORM TO DELIVER BETTER CARE AT LOWER COST

<u>CVS Health (NYSE: CVS)¹</u>	<u>Aetna (NYSE: AET)</u>
<ul style="list-style-type: none"> ~30,000 clinicians and lower-cost sites of care, including 1,100 MinuteClinic locations Pharmacy Advisor and other clinical programs provide rich pharmacy data that can drive better treatment adherence and insights Vast consumer touch points, with >70% of U.S. population living within 3 miles of a CVS Pharmacy location 	<ul style="list-style-type: none"> 22.2M medical members¹ across the U.S. and other locations Robust provider networks and healthcare services to improve patient outcomes across the care continuum National health insurance benefit platform can identify and target members to manage large commercial and government books; >\$44B in FY 2016 medical costs
<ul style="list-style-type: none"> Headquarters: Woonsocket, RI Leadership: Larry Merlo, President & CEO Employees: 250,000 2016 Revenue: \$177.5B 	<ul style="list-style-type: none"> Headquarters: Hartford, CT Leadership: Mark Bertolini, Chairman & CEO Employees: 49,500 2016 Revenue: \$63.2B
Pro Forma Financials² (\$, billions): Revenue: 221.4; Adj. EBITDA: 18.5; % Margin: 8.4%	

TRANSACTION OVERVIEW

- Equity value of \$69 billion; \$77 billion transaction value including the assumption of Aetna's debt
- Approximately \$207 per AET share in cash and stock, comprised of \$145 per share in cash and 0.8378 in CVS shares per AET share³
- CVS and AET shareholders will own 78% and 22% of combined company, respectively
- Expect transaction to close in the second half of 2018
- Subject to approval by CVS and AET shareholders, regulatory approvals and other customary closing conditions

VALUE CREATION HIGHLIGHTS

- Enhanced competitive positioning
- Low- to mid-single accretion in the second full year after close
- Ability to deliver \$750 million in near-term synergies; potential to deliver significant incremental value over the long-term
- Potential to generate significant new growth opportunities

GOVERNANCE

- Three Aetna directors, including Aetna Chairman and CEO Mark Bertolini, to be added to the CVS Health Board of Directors at closing
- Members of Aetna management team to play significant roles in the combined company
- Aetna will operate as stand-alone business unit of CVS Health led by members of the current management team

¹ Data as of September 30, 2017.

² Pro forma financials trailing 12 months through September 30, 2017.

³ Based on 5-Day Volume Weighted Average Price ending December 1, 2017, of \$74.21 per share.



No Offer or Solicitation

This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Additional Information and Where to Find It

In connection with the proposed transaction between CVS Health Corporation ("CVS Health") and Aetna Inc. ("Aetna"), CVS Health and Aetna will file relevant materials with the Securities and Exchange Commission (the "SEC"), including a CVS Health registration statement on Form S-4 that will include a joint proxy statement of CVS Health and Aetna that also constitutes a prospectus of CVS Health, and a definitive joint proxy statement/prospectus will be mailed to stockholders of CVS Health and shareholders of Aetna. INVESTORS AND SECURITY HOLDERS OF CVS HEALTH AND AETNA ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the registration statement and the joint proxy statement/prospectus (when available) and other documents filed with the SEC by CVS Health or Aetna through the website maintained by the SEC at <http://www.sec.gov>. Copies of the documents filed with the SEC by CVS Health will be available free of charge within the Investors section of CVS Health's Web site at <http://www.cvshealth.com/investors> or by contacting CVS Health's Investor Relations Department at 800-201-0938. Copies of the documents filed with the SEC by Aetna will be available free of charge on Aetna's internet website at <http://www.Aetna.com> or by contacting Aetna's Investor Relations Department at 860-273-8204.

Participants in Solicitation

CVS Health, Aetna, their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of CVS Health is set forth in its Annual Report on Form 10-K for the year ended December 31, 2016 ("CVS Health's Annual Report"), which was filed with the SEC on February 9, 2017, its proxy statement for its 2017 annual meeting of stockholders, which was filed with the SEC on March 31, 2017, and its Current Report on Form 8-K, which was filed with the SEC on May 12, 2017. Information about the directors and executive officers of Aetna is set forth in its Annual Report on Form 10-K for the year ended December 31, 2016 ("Aetna's Annual Report"), which was filed with the SEC on February 17, 2017, its proxy statement for its 2017 annual meeting of shareholders, which was filed with the SEC on April 7, 2017, and its Current Reports on Form 8-K, which were filed with the SEC on May 24, 2017 and October 2, 2017. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC when they become available.

Cautionary Statement Regarding Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 (the "Reform Act") provides a safe harbor for forward-looking statements made by or on behalf of CVS Health or Aetna. This communication may contain forward-looking statements within the meaning of the Reform Act. You can generally identify forward-looking statements by the use of forward-looking terminology such as "anticipate," "believe," "can," "continue," "could," "estimate," "evaluate," "expect," "explore," "forecast," "guidance," "intend," "likely," "may," "might," "outlook," "plan," "potential," "predict," "probable," "project," "seek," "should," "view," or "will," or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond CVS Health's and Aetna's control.

Statements in this communication regarding CVS Health and Aetna that are forward-looking, including CVS Health's and Aetna's projections as to the closing date for the pending acquisition of Aetna (the "transaction"), the extent of, and the time necessary to obtain, the regulatory approvals required for the transaction, the anticipated benefits of the transaction, the impact of the transaction on CVS Health's and Aetna's businesses, the expected terms and scope of the expected financing for the transaction, the ownership percentages of CVS Health's common stock of CVS Health stockholders and Aetna shareholders at closing, the aggregate amount of indebtedness of CVS Health following the closing of the transaction, CVS Health's expectations regarding debt repayment and its debt to capital ratio following the closing of the transaction, CVS Health's and Aetna's respective share repurchase programs and ability and intent to declare future dividend payments, the number of prescriptions used by people served by the combined companies' pharmacy benefit business, the synergies from the transaction, and CVS Health's, Aetna's and/or the combined company's future operating results, are based on CVS Health's and Aetna's managements' estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond their control. In particular, projected financial information for the combined businesses of CVS Health and Aetna is based on estimates, assumptions and projections and has not been prepared in conformance with the applicable accounting requirements of Regulation S-X relating to pro forma financial information, and the required pro forma adjustments have not been applied and are not reflected therein. None of this information should be considered in isolation from, or as a substitute for, the historical financial statements of CVS Health and Aetna. Important risk factors related to the transaction could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to: the timing to consummate the proposed transaction; the risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; the risk that a condition to the closing of the proposed transaction may not be satisfied; the ability to achieve the synergies and value creation contemplated; CVS Health's ability to promptly and effectively integrate Aetna's businesses; and the diversion of and attention of management of both CVS Health and Aetna on transaction-related issues.

In addition, this communication may contain forward-looking statements regarding CVS Health's or Aetna's respective businesses, financial condition and results of operations. These forward-looking statements also involve risks, uncertainties and assumptions, some of which may not be presently known to CVS Health or Aetna or that they currently believe to be immaterial also may cause CVS Health's or Aetna's actual results to differ materially from those expressed in the forward-looking statements, adversely impact their respective businesses, CVS Health's ability to complete the transaction and/or CVS Health's ability to realize the expected benefits from the transaction. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the transaction and/or CVS Health or Aetna, CVS Health's ability to successfully complete the transaction and/or realize the expected benefits from the transaction. Additional information concerning these risks, uncertainties and assumptions can be found in CVS Health's and Aetna's respective filings with the SEC, including the risk factors discussed in "Item 1.A. Risk Factors" in CVS Health's and Aetna's most recent Annual Reports on Form 10-K, as updated by their Quarterly Reports on Form 10-Q and future filings with the SEC.

You are cautioned not to place undue reliance on CVS Health's and Aetna's forward-looking statements. These forward-looking statements are and will be based upon management's then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. Neither CVS Health nor Aetna assumes any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date.

CVS Health + Aetna:
*Revolutionizing the Consumer
Health Care Experience*

♥ **CVS**Health



Important Information for Investors and Shareholders

No Offer or Solicitation

This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Additional Information and Where to Find It

In connection with the proposed transaction between CVS Health and Aetna, CVS Health and Aetna will file relevant materials with the Securities and Exchange Commission (the "SEC"), including a CVS Health registration statement on Form S-4 that will include a joint proxy statement of CVS Health and Aetna that also constitutes a prospectus of CVS Health, and a definitive joint proxy statement/prospectus will be mailed to stockholders of CVS Health and shareholders of Aetna. INVESTORS AND SECURITY HOLDERS OF CVS HEALTH AND AETNA ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the registration statement and the joint proxy statement/prospectus (when available) and other documents filed with the SEC by CVS Health or Aetna through the website maintained by the SEC at <http://www.sec.gov>. Copies of the documents filed with the SEC by CVS Health will be available free of charge within the Investors section of CVS Health's Web site at <http://www.CVSHealth.com/investors> or by contacting CVS Health's Investor Relations Department at 800-201-0938. Copies of the documents filed with the SEC by Aetna will be available free of charge on Aetna's internet website at <http://www.Aetna.com> or by contacting Aetna's Investor Relations Department at 860-273-8204.



Important Information for Investors and Shareholders

Participants in Solicitation

CVS Health, Aetna, their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of CVS Health is set forth in its Annual Report on Form 10-K for the year ended December 31, 2016 ("CVS Health's Annual Report"), which was filed with the SEC on February 9, 2017, its proxy statement for its 2017 annual meeting of stockholders, which was filed with the SEC on March 31, 2017, and its Current Report on Form 8-K, which was filed with the SEC on May 12, 2017. Information about the directors and executive officers of Aetna is set forth in its Annual Report on Form 10-K for the year ended December 31, 2016 ("Aetna's Annual Report"), which was filed with the SEC on February 17, 2017, its proxy statement for its 2017 annual meeting of shareholders, which was filed with the SEC on April 7, 2017 and its Current Reports on Form 8-K, which were filed with the SEC on May 24, 2017 and October 2, 2017. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC when they become available.

Cautionary Statement Regarding Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 (the "Reform Act") provides a safe harbor for forward-looking statements made by or on behalf of CVS Health or Aetna. This communication may contain forward-looking statements within the meaning of the Reform Act. You can generally identify forward-looking statements by the use of forward-looking terminology such as "anticipate," "believe," "can," "continue," "could," "estimate," "evaluate," "expect," "explore," "forecast," "guidance," "intend," "likely," "may," "might," "outlook," "plan," "potential," "predict," "probable," "project," "seek," "should," "view," or "will," or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond CVS Health's and Aetna's control.

Statements in this communication regarding CVS Health and Aetna that are forward-looking, including CVS Health's and Aetna's projections as to the closing date for the pending acquisition of Aetna (the "transaction"), the extent of, and the time necessary to obtain, the regulatory approvals required for the transaction, the anticipated benefits of the transaction, the impact of the transaction on CVS Health's and Aetna's businesses, the expected terms and scope of the expected financing for the transaction, the ownership percentages of CVS Health's common stock of CVS Health stockholders and Aetna shareholders at closing, the aggregate amount of indebtedness of CVS Health following the closing of the transaction, CVS Health's expectations regarding debt repayment and its debt to capital ratio following closing of the transaction, CVS Health's and Aetna's respective share repurchase programs and ability and intent to declare future dividend payments, the number of prescriptions used by people served by the combined companies' pharmacy benefit business, the synergies from the transaction, and CVS Health's, Aetna's and/or the combined company's future operating results, are based on CVS Health's and Aetna's managements' estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond their control. In particular, projected financial information for the combined businesses of CVS Health and Aetna is based on estimates, assumptions and projections and has not been prepared in conformance with the applicable accounting requirements of Regulation S-X relating to pro forma financial information, and the required pro forma adjustments have not been applied and are not reflected therein. None of this information should be considered in isolation from, or as a substitute for, the historical financial statements of CVS Health and Aetna. Important risk factors related to the transaction could

Cautionary Statement Regarding Forward-Looking Statements

cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to: the timing to consummate the proposed transaction; the risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; the risk that a condition to closing of the proposed transaction may not be satisfied; the ability to achieve the synergies and value creation contemplated; CVS Health's ability to promptly and effectively integrate Aetna's businesses; and the diversion of and attention of management of both CVS Health and Aetna on transaction-related issues.

In addition, this communication may contain forward-looking statements regarding CVS Health's or Aetna's respective businesses, financial condition and results of operations. These forward-looking statements also involve risks, uncertainties and assumptions, some of which may not be presently known to CVS Health or Aetna or that they currently believe to be immaterial also may cause CVS Health's or Aetna's actual results to differ materially from those expressed in the forward-looking statements, adversely impact their respective businesses, CVS Health's ability to complete the transaction and/or CVS Health's ability to realize the expected benefits from the transaction. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the transaction and/or CVS Health or Aetna, CVS Health's ability to successfully complete the transaction and/or realize the expected benefits from the transaction. Additional information concerning these risks, uncertainties and assumptions can be found in CVS Health's and Aetna's respective filings with the SEC, including the risk factors discussed in "Item 1.A. Risk Factors" in CVS Health's and Aetna's most recent Annual Reports on Form 10-K, as updated by their Quarterly Reports on Form 10-Q and future filings with the SEC.

You are cautioned not to place undue reliance on CVS Health's and Aetna's forward-looking statements. These forward-looking statements are and will be based upon management's then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. Neither CVS Health nor Aetna assumes any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date.

Compelling Strategic Rationale





Compelling Strategic Combination

- ✓ **Creates a leading health care platform** with unmatched suite of services
- ✓ **High-touch connectivity to consumers** as go-to local health care access point
- ✓ **Improved quality of care** through enhanced data integration /predictive analytics
- ✓ **Drives efficiencies and lower cost of care** through an integrated model
- ✓ **Highly diversified, strong and stable cash flows**
- ✓ **Significant synergy potential of \$750M in 2nd full year**; greater long-term opportunity
- ✓ **Low- to mid-single digit accretion expected in 2nd full year**; no meaningful impact in year one

CVS Health + Aetna: the best value creation opportunity for our shareholders



CVS Health-Aetna Combination Will Help Address U.S. Health Care System Challenges

Growth in Health Care Expenditures	Aging U.S. Population	Increasing Health Care Consumerism	Movement To Value-Based Care
<ul style="list-style-type: none"> Integrating medical and pharmacy benefits with consumer touchpoints to improve outcomes and lower costs 	<ul style="list-style-type: none"> More competitive Medicare Advantage and Part D offerings enable efficiencies and complementary expertise 	<ul style="list-style-type: none"> Broad market access Unique customer touchpoints Digital assets to drive patient engagement 	<ul style="list-style-type: none"> Combined assets promote lower-cost sites of care and enhanced clinical care programs
<p>CVS Health + Aetna will result in significant benefits to stakeholders</p>			

To Compete in the Future, a Number of New Assets and Capabilities Will Be Required

Traditional bases of competition needed but not sufficient

Contract with providers for best price

Underwrite risk

Manage utilization



Additional capabilities required going forward

Ability to reach patients and influence behavior

New ways of identifying (e.g., data and predictive analytics) and engaging patients to drive behavior change will be critical to lowering medical costs for patients and payors

Access to high-quality, lower-cost sites of care

Lower-cost models of care delivery will be crucial given margin compression and shift to value-based care

Strong health care services assets

Tools / services to lower costs and improve outcomes for own members and which can be sold to other health plans / providers

Winning in government business

Ability to improve member outcomes and effectively manage complex patients

CVS Health and Aetna Bring Unique and Differentiated Capabilities to the Combination




- ✓ Unparalleled reach that positions us as the front door to health care
- ✓ Ability to support patients, payors and providers with innovative, channel-agnostic solutions
- ✓ Broad capabilities to holistically manage patients
- ✓ Deep clinical expertise and insights
- ✓ Leading provider of pharmacy services in long-term care
- ✓ Unmatched scale in the U.S. making us low-cost provider



- ✓ World class consumer health and engagement model
- ✓ Leading health financing platform
- ✓ Best-in-class service
- ✓ Targeted solutions to improve health and wellness
- ✓ Differentiated provider collaboration experience – equipping providers with tools to succeed
- ✓ Innovative plan designs

Integrated Health Care Platform Offers Better Care and Convenience at a Lower Cost



Member and client benefits

- Better clinical outcomes from combination of medical and pharmacy claims data
- Increased patient satisfaction from enhanced consumer engagement
- More convenient care from access to "Health Care Hub"
- Lower cost to the patient and client
- Increased speed and efficiency of treatment

Example: CVS Health + Aetna Can Help Better Manage Medical Cost for Chronic Patients

Components of care delivery model

	Access to care	Patient engagement	Alignment across providers	Post-discharge
Pain points in current model	Inconvenient and inaccessible health care delivery system	Insufficient time to fully manage patient population	Lack of coordination to address gaps in care/unaligned incentives	Lack of support after a medical event
Ways CVS Health + Aetna can improve	Convenient locations and "last mile" presence In-home and local community-based care	New forms of patient interactions to supplement physician office visits Enhanced consumer experience	Value-based provider relationships Combined pharmacy and medical data – single source for patient records	Transitions of care, along with care coaches /pharmacists and other programs

Transaction Summary



Key Transaction Terms


<p>Purchase Price</p>	<ul style="list-style-type: none"> Equity value of \$69 billion. Including the assumption of Aetna debt, total transaction value of \$77 billion. Approximately \$207 per Aetna share in cash and stock, comprised of \$145.00 in cash and 0.8378 in CVS shares per AET share*
<p>Ownership</p>	<ul style="list-style-type: none"> CVS shareholders will own 78% of combined company AET shareholders will own 22% of combined company
<p>Management & Board of Directors</p>	<ul style="list-style-type: none"> 3 of Aetna's directors will be added at closing to CVS Health board of directors, including Mark T. Bertolini, Aetna chairman and CEO Members of Aetna management team will play significant roles in the combined company. Aetna will operate as a stand-alone business unit led by members of the current management team
<p>Closing</p>	<ul style="list-style-type: none"> Expect transaction to close in the second half of 2018 Subject to CVS and AET shareholder approvals, regulatory approvals and other customary closing conditions

*Based on 5-day Volume Weighted Average Price ending December 1, 2017, of \$74.21.

Creating a New Leader in Health Care

Revenue, Trailing Twelve Months

(\$, billions)



Creating a **Fortune 4** company with more than **\$18 billion** in pro forma adjusted EBITDA

Notes:

1. Managed care percentage allocated based on 2016 data. Shown as percent of total revenue.

Potential to Deliver \$750 Million of Synergies in Second Full Year

Traditional

- Streamline redundant corporate functions
- Improved pricing from third party vendors
- Combine PBM and PDP operations
- Improved enterprise dispensing

Medical Cost Reduction: Captured With Current Capabilities

- Improve care management by reducing overtreatment and failures of care delivery to drive reductions in wasteful medical spending
- Shift to lower cost sites of care using existing assets such as MinuteClinic and home infusions through Coram



Potential for Longer-Term Synergies to Deliver Significant Incremental Value

Medical Cost Reduction: Chronic Care Management	<ul style="list-style-type: none">• Improving chronic care management to reduce wasteful spending• Reducing readmissions via pharmacist-led interventions• Improving adherence to reduce medical spend
Medical Cost Reduction: Site of Care Shift	<ul style="list-style-type: none">• Reducing ER visits through the use of MinuteClinic• Shifting lab services to preferred sites through plan design and member education• Shifting infusion services out of outpatient hospital settings
Increased Medicare Presence	<ul style="list-style-type: none">• Improving select measures in Medicare Star rating criteria• Driving growth in Medicare Advantage
Growth in Membership	<ul style="list-style-type: none">• Growing customer base through unique set of offerings for the retail, PBM and managed care platforms



Continue to Execute Disciplined Long-Term Financial Policies

New debt of \$45 billion will result in pro forma leverage of approximately 4.6x; expect to deleverage rapidly

We are committed to sustaining a strong investment grade capital structure and will continue to follow disciplined financial policies

Leverage	Focus on deleveraging to low 3x adj. debt to adj. EBITDA to maintain strong balance sheet
Share Repurchases	Stop the share repurchase program until leverage is down to low 3x
Dividends	Keep dividends per share flat until leverage is down to low 3x
M&A Strategy	No additional major transactions contemplated
Capitalization	Insurance subsidiaries remain capitalized at existing strong investment grade financial strength ratings

Today's Key Takeaways CVS Health + Aetna: Significant Value Creation

Consumers	Benefit from uniquely integrated, community-based health care experience, helping them better navigate the system to achieve their best health
Clients	Helps address growing cost of treating chronic conditions through broader use of data and analytics, leading to improved patient health at substantially lower cost
Health Care System	Reduces wasteful spending by promoting lower cost sites of care and helping to avoid costly hospital readmissions
Investors	Low- to mid-single digit accretion in second full year after transaction close; clear line of sight to significant near- and longer-term synergies



Revolutionizing the Consumer Health Care Experience

Appendix: Financial Supplement



Sources and Uses of Funds

Sources
(\$B)

Available Cash	4.1
New Debt	44.8
New Equity Issued in Transaction	21.0
Total Sources	69.9

Uses
(\$B)

Purchase Equity	69.2
Other	0.7
Total Uses	69.9

Pro Forma Last Twelve Month Financial Profile

	 CVS Health	 aetna	Eliminations	Pro Forma
	(\$, billions)			
Revenue	182.4	61.4	(22.4)	221.4
Adjusted EBITDA	12.3	6.2		18.5
% Margin	6.7%	10.1%		8.4%

Refer to reconciliation to comparable GAAP measure on slides 23 and 24.

Non-GAAP Reconciliation – CVS Health Adjusted EBITDA

	TTM Q3 2017
Income from continuing operations	5,051
Income tax provision	3,161
Income before income tax provision	8,212
Interest expense, net	986
Depreciation and amortization	2,485
EBITDA	11,683
<i>Non-GAAP adjustments:</i>	
Acquisition-related integration costs	106
Losses on settlements of defined benefit pension plans	187
Charges in connection with store rationalization	245
Goodwill impairment	135
Adjustments to legal reserves in connection with legal settlements	(88)
Adjusted EBITDA	12,268

Source: Company filings. Calculated for the trailing twelve months ended September 30, 2017.

Non-GAAP Reconciliation – Aetna Adjusted EBITDA

	TTM Q3 2017
Income before income taxes	2,741
Interest expense	344
Loss on early extinguishment of long-term debt	246
Penn Treaty-related guaranty fund assessments	231
Transaction and integration-related costs	1,386
Restructuring costs	404
Reduction of reserve for anticipated future losses on discontinued products	(109)
Depreciation and amortization	669
Net realized capital (gains) losses	262
Adjusted EBITDA	6,174

Source: Company filings. Calculated for the trailing twelve months ended September 30, 2017.

Appendix: CVS Health Strengths and Capabilities



Leadership Across Multiple Segments

Retail Pharmacy	Pharmacy Benefits	Medicare Part D	Specialty Pharmacy	Long-Term Care Pharmacy	Retail Clinics
<ul style="list-style-type: none"> More than 9,700 locations across 49 states, Washington D.C., Puerto Rico and Brazil More than 1.1 billion retail scripts filled annually 	<ul style="list-style-type: none"> Nearly 90 million plan members Processed 1.6 billion claims More than \$43 billion in gross wins over past five seasons ~97% client retention in 2018 	<ul style="list-style-type: none"> SilverScript PDP with 5.5 million members Support Medicare Part D / MAPD offerings of health plans 	<ul style="list-style-type: none"> > 40% of Caremark's revenues Growth outpaces broader pharmacy market Infusion services through Coram 	<ul style="list-style-type: none"> Leading provider of pharmacy services to long-term care community Network of hub and spoke pharmacies to drive efficiency 	<ul style="list-style-type: none"> Providing high-quality care at a more affordable site More than 1,100 walk-in clinics across 33 states 37 million patient visits since inception

Data as of December 31, 2016.



Nationwide Retail Footprint Provides Direct Touchpoints with Consumers

Unsurpassed Reach

- ✓ More than 30,000 clinical professionals
- ✓ Nearly 70% of U.S. population lives within 3 miles of a CVS Pharmacy
- ✓ More than 50% of U.S. population lives within 10 miles of a MinuteClinic

Extensive Consumer Reach Across Many Platforms

Active Patient Base

Number of unique patients that fill an Rx each year in retail Pharmacy



65M

Clinical Message Reach


Automated calls or texts delivered to patients per year



1B

Phone Number Accuracy

Percent of patients with an accurate number on file



95%

ExtraCare Emails

Number of emails in ExtraCare database



55M

Text Message Enrollment

Number of active patients enrolled in text messaging



48M

Auto-Fulfillment Usage

Number of scripts filled via ReadyFill or ScriptSync / yr



144M

Patient Consultation

Number of pharmacist consultations per year in stores



140M


ExtraCare Offers

Number of ExtraCare offers issued in the last year



21B

We Make Data Actionable and Deliver It When and Where Interventions Can Do the Most Good



**Optimal Interventions
Powered by the
Health Engagement Engine**

Foundation of rich data and analytic expertise

CVS Caremark Offers Unmatched Suite of Cost Management Capabilities



Health care affordability improved as client trend lowered to

3.2%

Note: Trend based on full-year 2016 data from CVS commercial client cohort (health plans & employers).

Appendix: Aetna Strengths and Capabilities





Aetna is a Leading Health Services Company

44.6M* Unique Members

- ✓ 22.2M* medical members
- ✓ Over 70% of the Fortune 100 use Aetna
- ✓ 3rd largest publicly traded managed care organization
- ✓ Aetna members projected to use ~225m Adjusted Rx in 2017

Leading Medicare Franchise

- ✓ One of the fastest growing Medicare franchises
- ✓ Highest percentage of Medicare Advantage members in 4+ star plans amongst publicly-traded peers
- ✓ 2nd largest Group Medicare company

Strong Clinical Assets

- ✓ Over 5,200 nurses and over 300 doctors on staff
- ✓ High touch, high tech member service model
- ✓ Global network of providers


Next Generation Capabilities

- ✓ World class digital and analytics capabilities
- ✓ Suite of clinical decision support assets
- ✓ Extensive next generation provider network

*As of September 30, 2017; Note unique members includes Group Insurance

Nationwide, Geographically Diverse Membership

As of September 30, 2017, Aetna provides health benefits and services for **~22.2** million medical members across the U.S. and other locations



- <50K members
- 50K – 100K members
- 100K – 200K members
- 200K – 500K members
- 500K – 1M members
- >2M members



Aetna's Extensive Next Generation Provider Network

Extensive Provider Network

1.3 Million




Participating Health Care Providers

700,000



Primary Care Specialist Physicians

5,700



Hospitals

DEGREE OF PROVIDER RISK

JV health plan

Risk-bearing entity

Retail partnerships

ACO product

Value-based contracting

Fee-for Service

Align incentives and collaborate with providers to:

- Help providers build the health experience of the future
- Integrate data into EMR/provider workflows
- Improve member health
- Deliver a differentiated patient experience
- Improve quality and efficiency

Access to membership to increase provider engagement and collaboration

Increase provider's role to deliver consumer engagement and care model


AETNA FOCUS

Aetna's value-based strategy

Working with providers to redefine our relationships and align incentives



Focused on Improving Consumer Health and Engagement



Shareholders Expected to Benefit from a Number of Outcomes

Benefits for Shareholders

- ✓ Enhanced competitive positioning
- ✓ **Low- to mid-single digit** accretion in the second full year after close of the transaction *
- ✓ Ability to deliver **\$750 million** in near-term synergies
- ✓ A platform from which to accelerate growth
- ✓ Over the longer-term, potential to deliver **significant incremental value** through development of new products as a uniquely integrated retailer, pharmacy benefits manager and health plan

* Accretion is calculated as a percent of Adjusted EPS based upon First Call consensus figures immediately prior to the announcement of the transaction.